Reata Pharmaceuticals Competitors and Similar CompaniesClear all

Reata Pharmaceuticals's competitors and similar companies include Apellis Pharmaceuticals, Alnylam, Ionis Pharmaceuticals and Kadmon.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals
Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds.
Alnylam
Alnylam
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Kadmon
Kadmon
Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.
Founding Date
Founding Date
2002
Founding Date
2009
Founding Date
2002
Founding Date
1989
Founding Date
2010
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
Waltham, US HQ
Kew East, AU
München, DE
Zug, CH
San Francisco, US
Watertown, US
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Locations
Carlsbad, US HQ
Locations
New York, US HQ
Cambridge, US
South Brunswick Township, US
Warrendale, US
Employees
Employees
3217% decrease
Employees
7028% decrease
Employees
1,32324% increase
Employees
92716% increase
Employees
43
Valuation ($)
Valuation ($)
6.6 b
Valuation ($)
3.3 b
Valuation ($)
36.5 b
Valuation ($)
6.3 b
Valuation ($)
N/A

Financial

Revenue (est.)
Revenue (est.)
$2.2m (FY, 2022)
Revenue (est.)
$396.6m (FY, 2023)
Revenue (est.)
$1.8b (FY, 2023)
Revenue (est.)
$787.6m (FY, 2023)
Revenue (est.)
$8.3m (FY, 2020)
Cost of goods
Cost of goods
N/A
Cost of goods
$58.5m (FY, 2023)
Cost of goods
$268.2m (FY, 2023)
Cost of goods
$9.1m (FY, 2023)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$338.1m (FY, 2023)
Gross profit
$1.6b (FY, 2023)
Gross profit
$778.5m (FY, 2023)
Gross profit
N/A
Net income
Net income
($311.9m) (FY, 2022)
Net income
($528.6m) (FY, 2023)
Net income
($440.2m) (FY, 2023)
Net income
($366.3m) (FY, 2023)
Net income
($108.9m) (FY, 2020)

Operating

Phase I Trials Products
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2023)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
13 (FY, 2023)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
9 (FY, 2023)
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
$ 468.9m
Total funding raised
$ 88m
Total funding raised
$ 1.5b
Total funding raised
N/A
Total funding raised
$ 21.3m
For sources of this data, please see the company profile

View Company Profiles

Apellis Pharmaceuticals
HQ
Waltham, US
Employees
702↓ 8% decrease

Apellis Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds.

View company
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase

Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.

View company
Ionis Pharmaceuticals
HQ
Carlsbad, US
Employees
927↑ 16% increase

Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.

View company
Kadmon
HQ
New York, US

Kadmon Corporation is a biopharmaceutical company offering products and services for the treatment and management of hepatitis C.

View company